Antibody recognition of the dengue virus proteome and implications for development of vaccines

Clinical and Vaccine Immunology

Volumn 18, Issue 4, 2011, Pages 523-532

  Fernandez, Stefan ^a   Cisney, Emily D ^a   Tikhonov, Alexander P ^b   Schweitzer, Barry ^b   Putnak, Robert J ^c   Simmons, Monika ^c   Ulrich, Robert G ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Life Technologies   (United States)

^c NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; DENGUE VACCINE; IMMUNOGLOBULIN G; INACTIVATED VIRUS VACCINE; LIVE VACCINE; MEMBRANE PROTEIN; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 2A; NONSTRUCTURAL PROTEIN 2B; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS; IMMUNOGLOBULIN BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN MICROARRAY; RHESUS MONKEY; SEROTYPE;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DENGUE VACCINES; DENGUE VIRUS; MACACA MULATTA; MICROARRAY ANALYSIS; PROTEIN ARRAY ANALYSIS; VIRAL PROTEINS;

EID: 79954460547     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00016-11     Document Type: Article

References (44)

1. Adams, B., et al. 2006. Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc. Natl. Acad. Sci. U. S. A. 103:14234-14239.
2. Amexis, G., and N. S. Young. 2006. Parvovirus B19 empty capsids as antigen carriers for presentation of antigenic determinants of dengue 2 virus. J. Infect. Dis. 194:790-794.
3. Calvert, A. E., C. Y. Huang, R. M. Kinney, and J. T. Roehrig. 2006. Nonstructural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge. J. Gen. Virol. 87:339-346.
4. Chao, D. Y., et al. 2005. Strategically examining the full-genome of dengue virus type 3 in clinical isolates reveals its mutation spectra. Virol. J. 2:72.
5. Chung, K. M., B. S. Thompson, D. H. Fremont, and M. S. Diamond. 2007. Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile virus-infected cells. J. Virol. 81:9551-9555.
6. Churdboonchart, V., N. Bhamarapravati, S. Peampramprecha, and S. Sirinavin. 1991. Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 44:481-493.
7. Dejnirattisai, W., et al. 2010. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328:745-748.
8. Delenda, C., M. P. Frenkiel, and V. Deubel. 1994. Protective efficacy in mice of a secreted form of recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells. Arch. Virol. 139:197-207.
9. Delgado, M. F., et al. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15:34-41.
10. Eckels, K. H., et al. 2003. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am. J. Trop. Med. Hyg. 69:12-16.
11. Falconar, A. K. 1999. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch. Virol. 144:2313-2330.
12. Falconar, A. K. 2008. Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines. Clin. Vaccine Immunol. 15:549-561.
13. Falgout, B., M. Bray, J. J. Schlesinger, and C. J. Lai. 1990. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J. Virol. 64:4356-4363.
14. + cytotoxic T-lymphocyte clones. J. Virol. 70:141-147.
15. Gubler, D. J. 1998. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11:480-496.
16. Halstead, S. B., C. N. Venkateshan, M. K. Gentry, and L. K. Larsen. 1984. Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies. J. Immunol. 132:1529-1532.
17. Hermida, L., et al. 2006. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24:3165-3171.
18. Kaufman, B. M., P. L. Summers, D. R. Dubois, and K. H. Eckels. 1987. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 36:427-434.
19. Keasey, S. L., et al. 2009. Extensive antibody cross-reactivity among infectious gram-negative bacteria revealed by proteome microarray analysis. Mol. Cell. Proteomics 8:924-935.
20. Kliks, S. C., S. Nimmanitya, A. Nisalak, and D. S. Burke. 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38:411-419.
21. Kroeger, A., M. Nathan, and J. Hombach. 2004. Dengue. Nat. Rev. Microbiol. 2:360-361.
22. + cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. J. Clin. Invest. 98:1684-1691.
23. Michaud, G. A., et al. 2003. Analyzing antibody specificity with whole proteome microarrays. Nat. Biotechnol. 21:1509-1512.
24. Modis, Y., S. Ogata, D. Clements, and S. C. Harrison. 2005. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J. Virol. 79:1223-1231.
25. Morens, D. M., and S. B. Halstead. 1987. Disease severity-related antigenic differences in dengue 2 strains detected by dengue 4 monoclonal antibodies. J. Med. Virol. 22:169-174.
26. Mukhopadhyay, S., R. J. Kuhn, and M. G. Rossmann. 2005. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3:13-22.
27. Noisakran, S., and G. C. Perng. 2008. Alternate hypothesis on the pathogenesis of dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS) in dengue virus infection. Exp. Biol. Med. (Maywood) 233:401-408.
28. Predki, P. F., D. Mattoon, R. Bangham, B. Schweitzer, and G. Michaud. 2005. Protein microarrays: a new tool for profiling antibody cross-reactivity. Hum. Antibodies 14:7-15. (Pubitemid 43116918)
29. Putnak, J. R., et al. 2008. Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am. J. Trop. Med. Hyg. 79:115-122.
30. Puttikhunt, C., et al. 2009. Production and characterization of anti-dengue capsid antibodies suggesting the N terminus region covering the first 20 amino acids of dengue virus capsid protein is predominantly immunogenic in mice. Arch. Virol. 154:1211-1221.
31. Schlesinger, J. J., M. W. Brandriss, and E. E. Walsh. 1987. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J. Gen. Virol. 68(Pt. 3):853-857.
32. Schmid, K., et al. 2008. Analysis of the human immune response to vaccinia by use of a novel protein microarray suggests that antibodies recognize less than 10% of the total viral proteome. Proteomics Clin. Appl. 2:1528-2538.
33. Schweitzer, B., P. Predki, and M. Snyder. 2003. Microarrays to characterize protein interactions on a whole-proteome scale. Proteomics 3:2190-2199. (Pubitemid 37420040)
34. Shu, P. Y., et al. 2000. Dengue NS1-specific antibody responses: isotype distribution and serotyping in patients with Dengue fever and Dengue hemorrhagic fever. J. Med. Virol. 62:224-232.
35. Sierra, B., et al. 2002. Long-term memory cellular immune response to dengue virus after a natural primary infection. Int. J. Infect. Dis. 6:125-128.
36. Simmons, M., T. Burgess, J. Lynch, and R. Putnak. 2010. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 396:280-288.
37. Sun, W., et al. 2003. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am. J. Trop. Med. Hyg. 69(Suppl. 6):24-31.
38. Twiddy, S. S., E. C. Holmes, and A. Rambaut. 2003. Inferring the rate and time-scale of dengue virus evolution. Mol. Biol. Evol. 20:122-129.
39. Vaughn, D. W., et al. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181:2-9.
40. World Health Organization. 1997. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control, 2nd ed. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/resources/publications/dengue/ Denguepublication/en/.
41. World Health Organization. 2006. Scientific working group report on dengue. World Health Organization, Geneva, Switzerland. http://apps.who.int/tdr/ svc/publications/tdr-research-publications/swg-report-dengue.
42. Young, P. R., P. A. Hilditch, C. Bletchly, and W. Halloran. 2000. An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. J. Clin. Microbiol. 38:1053-1057.
43. Zhu, H., et al. 2001. Global analysis of protein activities using proteome chips. Science 293:2101-2105. (Pubitemid 32848060)
44. Zhu, H., et al. 2000. Analysis of yeast protein kinases using protein chips. Nat. Genet. 26:283-289.